NavariRMKoellerJM.Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother2003;37:1276–86. DOI 10.1345/aph.1C510.
2.
KuryshevYABrownAMWangLBenedictCRRampeD.Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther2000;295:614–20.
KeefeDL. The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: Is there cause for concern?Oncologist2002;7:65–72.
5.
KaiserRSezerOPapiesABauerSSchelenzCTremblayPBPatient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P- 450 2D6 genotypes. J Clin Oncol2002;20:2805–11.
6.
BernardSABrueraE.Drug interactions in palliative care. J Clin Oncol2000;18:1780–99.
